JP2019513725A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513725A5 JP2019513725A5 JP2018552062A JP2018552062A JP2019513725A5 JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5 JP 2018552062 A JP2018552062 A JP 2018552062A JP 2018552062 A JP2018552062 A JP 2018552062A JP 2019513725 A5 JP2019513725 A5 JP 2019513725A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- binds
- immune checkpoint
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201605947 | 2016-04-07 | ||
| GB1605947.9 | 2016-04-07 | ||
| PCT/EP2017/056469 WO2017174331A1 (en) | 2016-04-07 | 2017-03-17 | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513725A JP2019513725A (ja) | 2019-05-30 |
| JP2019513725A5 true JP2019513725A5 (enExample) | 2020-04-23 |
| JP7325959B2 JP7325959B2 (ja) | 2023-08-15 |
Family
ID=58358618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018552062A Active JP7325959B2 (ja) | 2016-04-07 | 2017-03-17 | 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190135925A1 (enExample) |
| EP (1) | EP3440109B1 (enExample) |
| JP (1) | JP7325959B2 (enExample) |
| KR (2) | KR20190017735A (enExample) |
| CN (1) | CN109476739A (enExample) |
| AU (1) | AU2017247880B2 (enExample) |
| BR (1) | BR112018070636A2 (enExample) |
| CA (1) | CA3020204A1 (enExample) |
| CL (2) | CL2018002828A1 (enExample) |
| ES (1) | ES3046543T3 (enExample) |
| IL (1) | IL262129B2 (enExample) |
| MX (1) | MX2018012319A (enExample) |
| PL (1) | PL3440109T3 (enExample) |
| RU (1) | RU2759970C2 (enExample) |
| WO (1) | WO2017174331A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| CA3020204A1 (en) | 2016-04-07 | 2017-10-12 | Cancer Research Technology Limited | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| GB201712032D0 (en) | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| CA3088856A1 (en) * | 2018-01-10 | 2019-07-18 | Bioinvent International Ab | Novel combination and use of antibodies |
| CA3091181A1 (en) * | 2018-02-13 | 2019-08-22 | Precision Biologics, Inc. | Methods and compositions for targeting treg cells |
| US11814434B2 (en) | 2018-03-13 | 2023-11-14 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| EP3566718A1 (en) * | 2018-05-07 | 2019-11-13 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer |
| EP3830129A4 (en) * | 2018-07-30 | 2022-05-04 | Invenra, Inc. | MULTISPECIFIC TREG-BINDING MOLECULES |
| WO2020177627A1 (zh) * | 2019-03-02 | 2020-09-10 | 上海一宸医药科技有限公司 | 一种双特异抗体 |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
| ES2975410T3 (es) * | 2020-02-13 | 2024-07-05 | UCB Biopharma SRL | Anticuerpos biespecíficos que se unen a HVEM y CD9 |
| CN115397860B (zh) * | 2020-05-14 | 2025-06-13 | 江苏恒瑞医药股份有限公司 | 抗cd25抗体、其抗原结合片段及其医药用途 |
| WO2022104009A1 (en) * | 2020-11-13 | 2022-05-19 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| EP4255929A2 (en) | 2020-12-02 | 2023-10-11 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| CN117916266A (zh) | 2021-09-02 | 2024-04-19 | 弗哈夫曼拉罗切有限公司 | 用于治疗aml的抗体 |
| TW202336033A (zh) * | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
| WO2023208990A1 (en) | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| KR20240113400A (ko) * | 2023-01-11 | 2024-07-22 | 한국과학기술원 | 종양 내 Treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| CN120584138A (zh) | 2023-02-06 | 2025-09-02 | 豪夫迈·罗氏有限公司 | 组合疗法及其用途 |
| EP4692351A1 (en) | 2023-03-29 | 2026-02-11 | Daiichi Sankyo Company, Limited | Anti-cd25 antibody and anti-cd25 antibody-drug conjugate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540555A (en) * | 2002-11-15 | 2008-04-30 | Genmab As | Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| JP2010504356A (ja) * | 2006-09-20 | 2010-02-12 | ザ ジョンズ ホプキンス ユニバーシティー | 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法 |
| WO2010030002A1 (ja) | 2008-09-12 | 2010-03-18 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| EP3421495A3 (en) | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CA3020204A1 (en) | 2016-04-07 | 2017-10-12 | Cancer Research Technology Limited | Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion |
| GB201712032D0 (en) * | 2017-07-26 | 2017-09-06 | Bioinvent Int Ab | Antibodies and uses thereof |
| US11814434B2 (en) * | 2018-03-13 | 2023-11-14 | Tusk Therapeutics Ltd. | Anti-CD25 for tumour specific cell depletion |
| WO2023208990A1 (en) * | 2022-04-26 | 2023-11-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist, |
-
2017
- 2017-03-17 CA CA3020204A patent/CA3020204A1/en active Pending
- 2017-03-17 WO PCT/EP2017/056469 patent/WO2017174331A1/en not_active Ceased
- 2017-03-17 US US16/091,350 patent/US20190135925A1/en not_active Abandoned
- 2017-03-17 MX MX2018012319A patent/MX2018012319A/es unknown
- 2017-03-17 ES ES17711664T patent/ES3046543T3/es active Active
- 2017-03-17 JP JP2018552062A patent/JP7325959B2/ja active Active
- 2017-03-17 IL IL262129A patent/IL262129B2/en unknown
- 2017-03-17 EP EP17711664.7A patent/EP3440109B1/en active Active
- 2017-03-17 BR BR112018070636-1A patent/BR112018070636A2/pt not_active Application Discontinuation
- 2017-03-17 AU AU2017247880A patent/AU2017247880B2/en active Active
- 2017-03-17 RU RU2018135247A patent/RU2759970C2/ru active
- 2017-03-17 PL PL17711664.7T patent/PL3440109T3/pl unknown
- 2017-03-17 CN CN201780022552.4A patent/CN109476739A/zh active Pending
- 2017-03-17 KR KR1020187032183A patent/KR20190017735A/ko not_active Ceased
- 2017-03-17 KR KR1020227006876A patent/KR20220032642A/ko not_active Ceased
-
2018
- 2018-10-04 CL CL2018002828A patent/CL2018002828A1/es unknown
-
2019
- 2019-11-29 CL CL2019003498A patent/CL2019003498A1/es unknown
-
2022
- 2022-03-28 US US17/706,028 patent/US20230265200A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513725A5 (enExample) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| US11230598B2 (en) | Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors | |
| WO2016070051A4 (en) | Combination therapy for treatment of disease | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2019500891A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP7680208B2 (ja) | 抗ｃｄ２７抗体およびその使用 | |
| JP2019500892A5 (enExample) | ||
| JP2020514363A (ja) | 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５ | |
| JP2018520657A5 (enExample) | ||
| KR20160037989A (ko) | 면역 자극을 위한 cd27 효능제와 면역 체크포인트 억제의 조합 | |
| IL263611A (en) | Antibodies specific to PD-L1 and methods of using them | |
| JP2017537892A5 (enExample) | ||
| JP2019518721A5 (enExample) | ||
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| JP2020502147A5 (enExample) | ||
| RU2018126297A (ru) | Антитела, нацеленные на cd32b, и способы их применения | |
| JP2018528776A5 (enExample) | ||
| CN111542544A (zh) | 用于治疗癌症的免疫刺激性激动性抗体 | |
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2020528765A5 (enExample) | ||
| WO2021080920A2 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| JP2024536383A (ja) | 併用におけるｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤 | |
| JPWO2019195452A5 (enExample) |